Breast lumps differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
| Line 60: | Line 60: | ||
! | ! | ||
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation | ! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation | ||
! colspan=" | ! colspan="3" rowspan="2" |Paraclinical findings | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard diagnosis | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard diagnosis | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
| Line 70: | Line 70: | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
!Benign | !Benign | ||
| Line 82: | Line 80: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |LAP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Others | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab findings | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
!Imaging | |||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
| Line 98: | Line 96: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| | | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| Line 119: | Line 116: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| | | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| Line 130: | Line 126: | ||
! | ! | ||
!Fibrocystic change | !Fibrocystic change | ||
! | ! | ||
! | ! | ||
| Line 161: | Line 156: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| | | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| Line 170: | Line 164: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! | ! | ||
! | ! | ||
| Line 193: | Line 186: | ||
! | ! | ||
!Cysts of montgomery | !Cysts of montgomery | ||
! | ! | ||
! | ! | ||
| Line 214: | Line 206: | ||
! | ! | ||
![[Fibroadenoma|Breast adenoma]] | ![[Fibroadenoma|Breast adenoma]] | ||
! | ! | ||
! | ! | ||
| Line 235: | Line 226: | ||
! | ! | ||
![[Hamartoma]] | ![[Hamartoma]] | ||
! | ! | ||
! | ! | ||
| Line 256: | Line 246: | ||
! | ! | ||
![[Hemangioma]] | ![[Hemangioma]] | ||
! | ! | ||
! | ! | ||
| Line 287: | Line 276: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| | | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| Line 298: | Line 286: | ||
! | ! | ||
!Mastitis | !Mastitis | ||
! | ! | ||
! | ! | ||
| Line 319: | Line 306: | ||
! | ! | ||
!Breast carcinoma | !Breast carcinoma | ||
! | ! | ||
! | ! | ||
| Line 340: | Line 326: | ||
! | ! | ||
!Ductal carcinoma in situ | !Ductal carcinoma in situ | ||
! | ! | ||
! | ! | ||
| Line 361: | Line 346: | ||
! | ! | ||
!'''Microinvasive breast cancer''' | !'''Microinvasive breast cancer''' | ||
! | ! | ||
! | ! | ||
| Line 382: | Line 366: | ||
! | ! | ||
!Breast sarcoma | !Breast sarcoma | ||
! | ! | ||
! | ! | ||
| Line 403: | Line 386: | ||
! | ! | ||
!Paget disease | !Paget disease | ||
! | ! | ||
! | ! | ||
| Line 424: | Line 406: | ||
! | ! | ||
![[Phyllodes tumor]] | ![[Phyllodes tumor]] | ||
! | ! | ||
! | ! | ||
| Line 445: | Line 426: | ||
! | ! | ||
!Lymphoma | !Lymphoma | ||
! | ! | ||
! | ! | ||
| Line 466: | Line 446: | ||
! | ! | ||
!Metastasis | !Metastasis | ||
! | ! | ||
! | ! | ||
| Line 485: | Line 464: | ||
! | ! | ||
|- | |- | ||
! | ! | ||
! | ! | ||
| Line 506: | Line 484: | ||
! | ! | ||
|- | |- | ||
! | ! | ||
! | ! | ||
| Line 529: | Line 506: | ||
! | ! | ||
!Duct ectasia | !Duct ectasia | ||
! | ! | ||
! | ! | ||
| Line 550: | Line 526: | ||
! | ! | ||
!Intraductal [[papilloma]] | !Intraductal [[papilloma]] | ||
! | ! | ||
! | ! | ||
| Line 571: | Line 546: | ||
! | ! | ||
!Lipoma | !Lipoma | ||
! | ! | ||
! | ! | ||
| Line 592: | Line 566: | ||
! | ! | ||
![[Neurofibroma]] | ![[Neurofibroma]] | ||
! | ! | ||
! | ! | ||
| Line 613: | Line 586: | ||
! | ! | ||
!Pregnancy | !Pregnancy | ||
! | ! | ||
! | ! | ||
| Line 634: | Line 606: | ||
! | ! | ||
!Gynecomastia | !Gynecomastia | ||
! | ! | ||
! | ! | ||
| Line 655: | Line 626: | ||
! | ! | ||
!Premenstrual syndrome | !Premenstrual syndrome | ||
! | ! | ||
! | ! | ||
| Line 676: | Line 646: | ||
! | ! | ||
!Breast trauma | !Breast trauma | ||
! | ! | ||
! | ! | ||
| Line 697: | Line 666: | ||
! | ! | ||
!Fat necrosis | !Fat necrosis | ||
! | ! | ||
! | ! | ||
| Line 718: | Line 686: | ||
! | ! | ||
!Drugs | !Drugs | ||
! | ! | ||
! | ! | ||
Revision as of 17:03, 12 January 2019
|
Breast lumps Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Breast lumps differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Breast lumps differential diagnosis |
|
Risk calculators and risk factors for Breast lumps differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Breast lumps must be differentiated from other diseases such as malignancy, cysts, inflammation and non-inflammatory solid lumps.
Breast symptoms such as nipple discharge and mastalgia require assessment as well [1].
Differentiating Breast lumps from other Diseases
Differential diagnosis of breast lumps include: [1]
- Malignancy or breast cancer
- Associated with following factors[2]:
- Geographical area
- Age
- Ethnicity
- Positive family history
- Pathology results such as:
- Atypical ductal hyperplasia (ADH)
- Atypical lobular hyperplasia (ALH)
- Lobular carcinoma in situ (LCIS)
- Previous history of radiotherapy
- Associated with following factors[2]:
- Inflammatory lumps:[3][4]
- Associated to personal habit and disease pattern:
- Infective lumps
- Non-infective lumps such as chronic granulomatous infection
- Associated to personal habit and disease pattern:
- Solid non-inflammatory lumps [5] [6]
- Related to age, geographical area and ethnicity
- Mostly fibroadenomas in women aged 20-30 years
- Phyllodes tumor are prevalent in various centers, racial groups in different frequencies
- Cysts[7]
- Related to age and usage of hormonal replacement therapy
- Symptomatic cysts are often seen in women age 30 years to early 50 years
- If menopausaed women may be present due to hormone replacement therapy (HRT)
| Benign | Palpable breast masses in women between 20 to 50 years old[8]The most common types of benign breast lumps are[9]:
|
|---|---|
| Malignant | The most common types are infiltrating ductal breast carcinoma, infiltrating lobular breast carcinoma, mixed of ductal and lobular carcinoma and usually present as a hard mass in breast[10] |
Differentiating Breast lumps from other Diseases
| Category | Diseases | Etiology | Clinical manifestation | Paraclinical findings | Gold standard diagnosis | Associated findings | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demography | History | Symptoms | Signs | |||||||||||||||
| Benign | Malignant | Mass | Pain | Nipple discharge | Breast exam | Skin changes | LAP | Others | Lab findings | Histopathology | Imaging | |||||||
| Fibroadenoma | ||||||||||||||||||
| Breast cyst | ||||||||||||||||||
| Fibrocystic change | ||||||||||||||||||
| Galactocele | ||||||||||||||||||
| Cysts of montgomery | ||||||||||||||||||
| Breast adenoma | ||||||||||||||||||
| Hamartoma | ||||||||||||||||||
| Hemangioma | ||||||||||||||||||
| Breast abscess | ||||||||||||||||||
| Mastitis | ||||||||||||||||||
| Breast carcinoma | ||||||||||||||||||
| Ductal carcinoma in situ | ||||||||||||||||||
| Microinvasive breast cancer | ||||||||||||||||||
| Breast sarcoma | ||||||||||||||||||
| Paget disease | ||||||||||||||||||
| Phyllodes tumor | ||||||||||||||||||
| Lymphoma | ||||||||||||||||||
| Metastasis | ||||||||||||||||||
| Duct ectasia | ||||||||||||||||||
| Intraductal papilloma | ||||||||||||||||||
| Lipoma | ||||||||||||||||||
| Neurofibroma | ||||||||||||||||||
| Pregnancy | ||||||||||||||||||
| Gynecomastia | ||||||||||||||||||
| Premenstrual syndrome | ||||||||||||||||||
| Breast trauma | ||||||||||||||||||
| Fat necrosis | ||||||||||||||||||
| Drugs | ||||||||||||||||||
References
- ↑ 1.0 1.1 Cheung KL, Lam TP (2005). "Approach to a lump in the breast: a regional perspective". Asian J Surg. 28 (1): 65–70. doi:10.1016/S1015-9584(09)60264-5. PMID 15691804.
- ↑ Collyar DE (2001). "Breast cancer: a global perspective". J Clin Oncol. 19 (18 Suppl): 101S–105S. PMID 11560983.
- ↑ Lang AP, Luchsinger IS, Rawling EG (1987). "Filariasis of the breast". Arch Pathol Lab Med. 111 (8): 757–9. PMID 3307689.
- ↑ Varghese R, Raghuveer CV, Pai MR, Bansal R (1996). "Microfilariae in cytologic smears: a report of six cases". Acta Cytol. 40 (2): 299–301. doi:10.1159/000333755. PMID 8629415.
- ↑ Alagaratnam, T.T. & Wong, J. World J. Surg. (1989) 13: 743. https://doi.org/10.1007/BF01658425
- ↑ Shukla HS, Kumar S (1989). "Benign breast disorders in nonwestern populations: Part II--Benign breast disorders in India". World J Surg. 13 (6): 746–9. PMID 2623884.
- ↑ Leung TN, Haines CJ, Chung TK (2001). "Five-year compliance with hormone replacement therapy in postmenopausal Chinese women in Hong Kong". Maturitas. 39 (3): 195–201. PMID 11574178.
- ↑ Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW (1998). "Ten-year risk of false positive screening mammograms and clinical breast examinations". N Engl J Med. 338 (16): 1089–96. doi:10.1056/NEJM199804163381601. PMID 9545356.
- ↑ Morrow M (2000). "The evaluation of common breast problems". Am Fam Physician. 61 (8): 2371–8, 2385. PMID 10794579.
- ↑ Schoonjans JM, Brem RF (2001). "Fourteen-gauge ultrasonographically guided large-core needle biopsy of breast masses". J Ultrasound Med. 20 (9): 967–72. PMID 11549157.